Client programs using CHOMax follow platform-defined workflows and phase-appropriate practices across the development lifecycle.

In the race to bring new biologics to market, development teams are constantly balancing speed, quality, and regulatory ...

Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, today announced the expansion of its LV Edge System with the launch of a fully stable cell line development ...

Adoptive therapies based on CAR/TCR T cells—that is, T cells with an engineered chimeric antigen receptor (CAR) or a T-cell receptor (TCR)—have shown promise for a range of cancers, offering hope to ...